» Articles » PMID: 34160014

CRISPR/Cas9-engineered Drosophila Knock-in Models to Study VCP Diseases

Overview
Journal Dis Model Mech
Specialty General Medicine
Date 2021 Jun 23
PMID 34160014
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in Valosin Containing Protein (VCP) are associated with several degenerative diseases, including multisystem proteinopathy (MSP-1) and amyotrophic lateral sclerosis. However, patients with VCP mutations vary widely in their pathology and clinical penetrance, making it difficult to devise effective treatment strategies. A deeper understanding of how each mutation affects VCP function could enhance the prediction of clinical outcomes and design of personalized treatment options. The power of a genetically tractable model organism coupled with well-established in vivo assays and a relatively short life cycle make Drosophila an attractive system to study VCP disease pathogenesis. Using CRISPR/Cas9, we have generated individual Drosophila knock-in mutants that include nine hereditary VCP disease mutations. Our models display many hallmarks of VCP-mediated degeneration, including progressive decline in mobility, protein aggregate accumulation and defects in lysosomal and mitochondrial function. We also made some novel and unexpected findings, including nuclear morphology defects and sex-specific phenotypic differences in several mutants. Taken together, the Drosophila VCP disease models generated in this study will be useful for studying the etiology of individual VCP patient mutations and testing potential genetic and/or pharmacological therapies.

Citing Articles

Human is sufficient to stimulate tubular lysosomes and extend healthspan in well-fed .

Gill J, DeLeo K, Bohnert K, Johnson A MicroPubl Biol. 2024; 2024.

PMID: 39554807 PMC: 11568451. DOI: 10.17912/micropub.biology.001379.


VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models.

Phan J, Creekmore B, Nguyen A, Bershadskaya D, Darwich N, Mann C J Clin Invest. 2024; 134(14).

PMID: 38787785 PMC: 11257039. DOI: 10.1172/JCI169039.


Sex matters in preclinical research.

Justice M Dis Model Mech. 2024; 17(3).

PMID: 38450661 PMC: 10941654. DOI: 10.1242/dmm.050759.


Restricting bioenergetic efficiency enhances longevity and mitochondrial redox capacity in Drosophila melanogaster.

Taylor A, Dubuisson O, Pandey P, Zunica E, Vandanmagsar B, Dantas W Aging Cell. 2024; 23(5):e14107.

PMID: 38343281 PMC: 11113268. DOI: 10.1111/acel.14107.


Fluvastatin-induced myofibrillar damage is associated with elevated ROS, and impaired fatty acid oxidation, and is preceded by mitochondrial morphological changes.

Al-Sabri M, Ammar N, Korzh S, Alsehli A, Hosseini K, Fredriksson R Sci Rep. 2024; 14(1):3338.

PMID: 38336990 PMC: 10858229. DOI: 10.1038/s41598-024-53446-w.


References
1.
Johnson A, Orr B, Fetter R, Moughamian A, Primeaux L, Geier E . SVIP is a molecular determinant of lysosomal dynamic stability, neurodegeneration and lifespan. Nat Commun. 2021; 12(1):513. PMC: 7820495. DOI: 10.1038/s41467-020-20796-8. View

2.
Weihl C, Pestronk A, Kimonis V . Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscul Disord. 2009; 19(5):308-15. PMC: 2859037. DOI: 10.1016/j.nmd.2009.01.009. View

3.
Muller J, Deinhardt K, Rosewell I, Warren G, Shima D . Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochem Biophys Res Commun. 2007; 354(2):459-65. DOI: 10.1016/j.bbrc.2006.12.206. View

4.
Regensburger M, Turk M, Pagenstecher A, Schroder R, Winkler J . VCP-related multisystem proteinopathy presenting as early-onset Parkinson disease. Neurology. 2017; 89(7):746-748. DOI: 10.1212/WNL.0000000000004240. View

5.
Valente A, Maddalena L, Robb E, Moradi F, Stuart J . A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture. Acta Histochem. 2017; 119(3):315-326. DOI: 10.1016/j.acthis.2017.03.001. View